This table lists all the major pharma collaborations, acquisitions and mergers agreed during August 2014.
For an indepth analysis of these deals, read ‘Pharma deals during August 2014’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| InterMune/ Roche | Company acquisition | Pirfenidone for idiopathic pulmonary fibrosis (IPF) (approved EU, Canada) | 8,300 |
| MannKind/ Sanofi | Licence | Afrezza (human insulin) Rapid-Acting Inhaled Insulin (approved US) | 925 |
| Charleston Laboratories/ Daiichi Sankyo* | Collaboration (co-promotion rights) | Hydrocodone combination products, inc CL-108, for acute pain and reduction of Opioid-Induced Nausea and Vomiting (OINV) (phase III) | 650 |
| Gamida Cell/ Novartis | Investment, option to acquire | Stem cell therapies including NiCord (phase I/II) | 635 |
| Beijing Jialin Pharma/ Luye Pharma | Company acquisition (58%) | CV and cancer drug portfolio | 600 |
| TARIS Biomedical/ Allergan | Company acquisition | LiRIS for interstitial cystitis / bladder pain syndrome (IC/BPS) (phase II) | 587.5 |
| Santaris/ Roche (pRED) | Company acquisition | Locked Nucleic Acid (LNA) platform for RNA-targeting therapeutics | 450 |
| Sapiens Steering Brain Stimulation/ Medtronic | Company acquisition | Deep brain stimulation technologies for neurodegenerative diseases e.g. PD and essential tremor | 200 |
| Dream Pharma/ Alvogen | Company acquisition | Generics | 187 |
| Emergent BioSolutions/ Morphosys** | Licence, joint development & commercialisation | MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical) | 183 |
| Immune Design/ Sanofi | Licence | GLAAS discovery platform to develop therapeutics for a selected food allergy | 168 |
| Guizhou Taibang Biological Products/ China Biologic | Company acquisition (19.84% stake) | Plasma-based products | 87.1+ |
| Ziopharm Oncology/ Solasia Pharma | Amendment of 2011 licence/ collaboration | Darinaparsin (Zinapar or ZIO-101) and related organoarsenic molecules | 72.2 |
| Millennium (Takeda)/ Infinity Pharma | Option to buy out future potential royalties | IPI-145 for treatment of blood cancers (phase III) | 57.5 |
| Rush University Medical Center/ DRI Capital | Acquisition of royalty rights | Ampyra (dalfampridine) extended release tablets (marketed) | 42 |
| Alpine Biosciences/ Oncothyreon | Company acquisition | Protocells, nanoparticle technology for targeted delivery of nucleic acids, proteins, peptides, small molecules (platform) | 27 |
| Valeo Pharma/ Valeant | Product portfolio acquisition | Dermatology brands and specialty products | 25.3 |
| ViaCyte/ Janssen R&D | Rights agreement | VC-01 based on pancreatic progenitor cells to treat type 1 diabetes (preclinical) | 20 |
| Hanmi Pharm/ Luye Pharma† | Licence | Poziotinib, a pan-HER inhibitor for the treatment of cancer (phase II) | 20 |
| Abbott/ US Department of Defense | Collaboration | To develop portable blood tests to evaluate potential concussions or mild traumatic brain injuries (TBIs) | 19.5 |
All deals are worldwide unless otherwise noted.
* US
** ww excluding US and Canada
† China